Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
34 stopped studies mapped to Endometrial Carcinoma and descendants · 94% state a reason
Over the 34 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT05316467 | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | Phase 2 / Phase 3 | terminated | Apr 7, 2022 | Xiaojun Chen | no enough enrolled patients | Enrollment / accrual |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer… | Phase 2 | terminated | Aug 31, 2022 | University of Oklahoma | Funding issue | Funding |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | Phase 1 / Phase 2 | withdrawn | Aug 28, 2025 | Centre Leon Berard | Molecule not available from the laboratory | Other (stated, no rule matched) |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable… | Phase 2 | terminated | Sep 8, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | Phase 2 / Phase 3 | terminated | Nov 12, 2019 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | — | withdrawn | Jan 14, 2022 | WellSpan Health | study was not started at WellSpan | Other (stated, no rule matched) |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk… | N/A | withdrawn | Sep 19, 2018 | Fudan University | This study was not approved by the Ethics Committee | Other (stated, no rule matched) |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT05390021 | PET/MRI in Endometrial Cancer | N/A | withdrawn | May 25, 2022 | Massachusetts General Hospital | Unable to enroll patients to study | Enrollment / accrual |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients… | Phase 3 | withdrawn | Feb 6, 2023 | EQRx International, Inc. | The study is being closed based on corporate changes at EQRx and is not related to any efficacy or… | Safety / toxicity |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk… | Phase 2 | terminated | Dec 30, 2009 | Albert Einstein College of Medicine | Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid. | Enrollment / accrual |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating… | Phase 2 | terminated | Apr 14, 2014 | Albert Einstein College of Medicine | Low accrual. Study formally terminated by PI on 12/1/2017 | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03945786 | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma | — | suspended | May 10, 2019 | Xuanwu Hospital, Beijing | Recuriting inclusion and exclusion criteria will be changed as COVID-19. | COVID-19 / pandemic |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed… | Phase 2 | terminated | Feb 2, 2006 | Carilion Clinic | Investigator abruptly left Carilion. | Investigator |
| NCT01939028 | Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery | N/A | terminated | Sep 11, 2013 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure due to slow/insufficient accrual. | Enrollment / accrual |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With… | Phase 3 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | Study drug no longer available resulting in lack of study drug for participants. | Other (stated, no rule matched) |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Phase 2 | withdrawn | Feb 11, 2019 | University of Oklahoma | Study was not initiated. | Other (stated, no rule matched) |
| NCT02868892 | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas | Phase 2 | terminated | Aug 16, 2016 | Western Regional Medical Center | departure of PI from institution and poor population for study participation | Other (stated, no rule matched) |
| NCT00070317 | Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1… | N/A | terminated | Oct 7, 2003 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01184053 | Trisenox® in Women With Metastatic Endometrial Cancer(NRR) | Phase 2 | terminated | Aug 18, 2010 | UNC Lineberger Comprehensive Cancer Center | Accrual was very low. No subject had been enrolled in a year. | Enrollment / accrual |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients… | Phase 2 | withdrawn | Sep 16, 2013 | University of Southern California | Lack of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials